Dispensing Study for a New Study Lens

November 5, 2020 updated by: CooperVision, Inc.

Dispensing Study for The Phenacite Project

This study investigated the performance criteria over one week of daily wear to determine if the comfilcon A asphere lens (test) performed equivalently to the comfilcon A sphere (control) in terms of measurement and subjective ratings of visual performance.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This study was a prospective, single site, daily wear, double masked, randomized bilateral cross over dispensing study of binocular wear of comfilcon A asphere lens (test) and comfilcon A sphere lens (control) over 1 week of daily wear.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
44

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Canada
    • Ontario
      • Waterloo, Ontario, Canada, N2L 3G1
        • Center for Contact Lens Research, University of Waterloo
  • United States
    • California
      • Berkeley, California, United States, 94720
        • University of California
    • Indiana
      • Bloomington, Indiana, United States, 47405
        • CORL, Indiana University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years to 35 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

A person is eligible for inclusion in the study if he/she:

  • Oculo-visual examination in the last two years
  • Between 18 and 35 years of age and has full legal capacity to volunteer
  • Has read and understood the informed consent letter
  • Is willing and able to follow instructions and maintain the appointment schedule
  • Is correctable to a visual acuity of 20/25 or better (in each eye) with their habitual correction or 20/20 best corrected
  • Currently wears, or has previously successfully worn, soft contact lenses between -1.00D (Diopoter) and -4.00D
  • Spherical Contact Lens Rx between -1.00 and -4.00 and spectacle cylinder <-0.75
  • Has not worn lenses for at least 12 hours before the initial visit
  • Has a subjective response at baseline, which indicates suitability for this study
  • Currently spends a minimum of 4 hours a day; 5 days a week on digital devices and can replicate this time during the study period
  • Is willing and able to wear the study contact lenses a minimum of 10 hours per day; 5 days a week

Exclusion Criteria:

A person will be excluded from the study if he/she:

  • Has never worn contact lenses before
  • Any systemic disease affecting ocular health
  • Is using any systemic or topical medications that will affect ocular health
  • Has known sensitivity to the diagnostic pharmaceuticals or study products used in this study.
  • Has any ocular pathology or anomaly that would affect the wearing of the lenses
  • Has persistent, clinically significant corneal or conjunctival staining using sodium fluorescein dye
  • Is aphakic
  • Has anisometropia of >1.00
  • Has undergone corneal refractive surgery
  • Has strabismus
  • Has any ocular amblyopia >= 1line of HC (High Contrast) Visual Acuity
  • Is participating in any other type of eye related clinical or research study
  • Has previously participated in study of the Phenacite lenses

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Phenacite Test lens then comfilcon A control lens
Participants were randomized to wear Phenacite test lens for one week then cross-over to wear comfilcon A control lens for one week.
Device: Phenacite
contact lens
Device: comfilcon A
contact lens
Active Comparator: Comfilcon A control lens then Phenacite test Lens
Participants were randomized to wear comfilcon A control lens for one week then cross over to Phenacite test lens for one week.
Device: Phenacite
contact lens
Device: comfilcon A
contact lens

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Distance Visual Acuity (VA) - High Illumination
Time Frame: Baseline (after 10 minutes of lens dispense)
Distance visual acuity High Illumination was assessed using logMAR
Baseline (after 10 minutes of lens dispense)
Distance Visual Acuity (VA) - High Illumination
Time Frame: 1 week
Distance visual acuity High Illumination was assessed using logMAR
1 week
Near Visual Acuity (VA) - High Illumination
Time Frame: Baseline (after 10 minutes of lens dispense)
Near Visual Acuity (VA) - High Illumination assessed using logMAR
Baseline (after 10 minutes of lens dispense)
Near Visual Acuity (VA) - High Illumination
Time Frame: 1 week
Near Visual Acuity (VA) - High Illumination assessed using logMAR
1 week
Distance Visual Acuity (VA) - Low Illumination
Time Frame: Baseline (after 10 minutes of lens dispense)
Distance Visual Acuity (VA) - Low Illumination assessed using logMAR
Baseline (after 10 minutes of lens dispense)
Distance Visual Acuity (VA) - Low Illumination
Time Frame: 1 week
Distance Visual Acuity (VA) - Low Illumination assessed using logMAR
1 week
Near Visual Acuity (VA) - Low Illumination
Time Frame: Baseline (after 10 minutes of lens dispense)
Near Visual Acuity (VA) - Low illumination assessed using logMAR
Baseline (after 10 minutes of lens dispense)
Near Visual Acuity (VA) - Low Illumination
Time Frame: 1 week
Near Visual Acuity (VA) - Low illumination assessed using logMAR
1 week
Quality of Distance Vision
Time Frame: Baseline (after 10 minutes of lens dispense)
Subjective scoring of Quality of Distance Vision assessed using 0-100 continuous scale: (0=extremely poor vision all of the time. 100=excellent vision all of the time)
Baseline (after 10 minutes of lens dispense)
Quality of Distance Vision
Time Frame: 1 week
Subjective scoring of Quality of Distance Vision assessed using 0-100 continuous scale: (0=extremely poor vision all of the time. 100=excellent vision all of the time)
1 week
Quality of Near Vision
Time Frame: Baseline (After 10 minutes of lens dispense)
Patient subjective scoring for quality of near vision using 0-100 continuous scale: 0=extremely poor vision all of the time. 100=excellent vision all of the time
Baseline (After 10 minutes of lens dispense)
Quality of Near Vision
Time Frame: 1 week
Patient subjective scoring for quality of near vision using 0-100 continuous scale: 0=extremely poor vision all of the time. 100=excellent vision all of the time
1 week
Quality of Vision With Digital Device Use
Time Frame: Baseline (After 10 minutes of lens dispense)
Subjective scoring of Quality of Vision with digital device use assessed using 0-100 continuous scale: (0=extremely poor vision all of the time. 100=excellent vision all of the time)
Baseline (After 10 minutes of lens dispense)
Quality of Vision With Digital Device Use
Time Frame: 1 week
Subjective scoring of Quality of Vision with digital device use assessed using 0-100 continuous scale: (0=extremely poor vision all of the time. 100=excellent vision all of the time)
1 week
Quality of Intermediate Vision
Time Frame: Baseline (After 10 minutes of lens dispense)
Subjective scoring of Quality of Intermediate Vision assessed using 0-100 continuous scale: (0=extremely poor vision all of the time. 100=excellent vision all of the time)
Baseline (After 10 minutes of lens dispense)
Quality of Intermediate Vision
Time Frame: 1 week
Subjective scoring of Quality of Intermediate Vision assessed using 0-100 continuous scale: (0=extremely poor vision all of the time. 100=excellent vision all of the time)
1 week
Overall Vision Quality
Time Frame: Baseline (After 10 minutes of lens dispense)
Subjective scoring of overall vision quality assessed using 0-100 continuous scale: (0=extremely poor vision all of the time. 100=excellent vision all of the time)
Baseline (After 10 minutes of lens dispense)
Overall Vision Quality
Time Frame: 1 week
Subjective scoring of overall vision quality assessed using 0-100 continuous scale: (0=extremely poor vision all of the time. 100=excellent vision all of the time)
1 week

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Biomicroscopy Findings - Bulbar Hyperemia
Time Frame: 1 week
Bulbar hyperemia assessment using 5 categories: (0=None, 1= Slight injection to conjunctival vessels, 2= Mild injection, 3= Moderate injection, 4= Severe injection) in (0.25 steps)
1 week
Biomicroscopy Findings- Limbal Hyperemia
Time Frame: 1 week
Investigator assessment using 5 categories: (0=None, 1= Slight injection to conjunctival vessels, 2= Mild injection, 3= Moderate injection, 4= Severe injection) in (0.25 steps)
1 week
Biomicroscopy Findings - Corneal Staining Extent
Time Frame: 1 week
Investigator Assessment on Biomicroscopy Findings - Corneal Staining Extent on a scale of 0-4 : 0=No staining, 1=1-15% of area, 2=16-30% of area, 3=31-45% of area, 4= >45% of area
1 week
Ghosting - Distance Vision
Time Frame: 1 week
Patient subjective scoring using 0-100 continuous scale:0=Intolerable;100=Not noticable
1 week
Ghosting - Near Vision
Time Frame: 1 week
Patient subjective scoring using 0-100 continuous scale:0=Intolerable;100=Not noticable
1 week
Overall Comfort
Time Frame: Baseline (After 10 minutes of lens dispense)
Patient subjective scoring using 0-100 continuous scale, 0= cannot be worn, 100= cannot be felt ever.
Baseline (After 10 minutes of lens dispense)
Overall Comfort
Time Frame: 1 week
Patient subjective scoring for overall comfort using 0-100 continuous scale, 0= cannot be worn, 100= cannot be felt ever.
1 week
Overall Dryness
Time Frame: Baseline (after 10 minutes of lens dispense)
Patient subjective scoring for overall dryness using 0-100 continuous scale, 0=cannot be worn, 100=no dryness experienced at any time.
Baseline (after 10 minutes of lens dispense)
Overall Dryness
Time Frame: 1 week
Patient subjective scoring for overall dryness using 0-100 continuous scale, 0=cannot be worn, 100=no dryness experienced at any time.
1 week
Lens Preference - Overall Vision Preference
Time Frame: 1 week
Subjective rating of lens preference for overall vision preference (Phenacite, comfilcon A, No preference)
1 week
Subjective Ratings of Change in Frequency of Tiredness
Time Frame: 1 week
Subjective rating of change in eye fatigue frequency of tiredness assessed using Eye fatigue Experience Questionnaire (EFEG)
1 week
Subjective Ratings of Change in Severity of Tiredness
Time Frame: 1 week
Subjective rating of change in eye fatigue severity of tiredness assessed using Eye fatigue Experience Questionnaire (EFEG)
1 week
Subjective Ratings of Change in Bothersome Rating for Tiredness
Time Frame: 1 week
Subjective rating of change in eye fatigue bothersome rating for tiredness assessed using Eye fatigue Experience Questionnaire (EFEG)
1 week
Subjective Ratings of Change in Frequency of Dryness
Time Frame: 1 week
Subjective rating of change in eye fatigue frequency of dryness assessed using Eye fatigue Experience Questionnaire (EFEG)
1 week
Subjective Ratings of Change in Severity of Dryness
Time Frame: 1 week
Subjective rating of change in eye fatigue severity of dryness assessed using Eye fatigue Experience Questionnaire (EFEG)
1 week
Subjective Ratings of Change in Bothersome Rating of Dryness
Time Frame: 1 week
Subjective rating of change in eye fatigue bothersome rating for dryness assessed using Eye fatigue Experience Questionnaire (EFEG)
1 week
Subjective Questionnaire Response - Eye Strain
Time Frame: 1 week
Subjective questionnaire response for " My eyes don't feel strained while wearing these lenses" - Agree, Disagree
1 week
Subjective Questionnaire Response - Eye Feel Good
Time Frame: 1 week
Subjective questionnaire response for " These lenses make my eyes feel good" - Agree, Disagree
1 week
Subjective Questionnaire Response - Eye Feel Relaxed
Time Frame: 1 week
Subjective questionnaire response for " These lenses make my eyes feel relaxed" - Agree, Disagree
1 week
Subjective Questionnaire Response - Vision
Time Frame: 1 week
Subjective questionnaire response for " These lenses help my vision" - Agree, Disagree
1 week
Subjective Questionnaire Response - Eye Tired
Time Frame: 1 week
Subjective questionnaire response for " These lenses make my eyes feel less tired" - Agree, Disagree
1 week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
CooperVision, Inc.

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Lyndon Jones, CCLR, University of Waterloo
  • Principal Investigator: Pete Kollbaum, OD, PhD, CORL, Indiana University
  • Principal Investigator: Meng Lin, OD, PhD, CRC, University of California, Berkeley

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
November 1, 2015

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
January 1, 2016

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
March 1, 2016

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
December 7, 2015

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
December 28, 2015

First Posted (Estimate)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
December 30, 2015

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
December 1, 2020

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 5, 2020

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
November 1, 2020

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • CV-15-41

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings